HIV Vaccines—where are we going?
- 1 May 1998
- journal article
- review article
- Published by Springer Nature in Nature Medicine
- Vol. 4 (S5) , 532-534
- https://doi.org/10.1038/nm0598supp-532
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteersProceedings of the National Academy of Sciences, 1997
- Chemokines and HIV–1 second receptorsNature Medicine, 1996
- Phenotypic Analysis of Antigen-Specific T LymphocytesScience, 1996
- Neutralizing and Infection-Enhancing Antibody Responses to Human Immunodeficiency Virus Type 1 in Long-Term NonprogressorsThe Journal of Infectious Diseases, 1996
- Use of DNAs Expressing HIV-1 Env and Noninfectious HIV-1 Particles to Raise Antibody Responses in MiceVirology, 1995
- Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1995
- Virologic and Immunologic Characterization of Long-Term Survivors of Human Immunodeficiency Virus Type 1 InfectionNew England Journal of Medicine, 1995
- Genotypic and Phenotypic Characterization of HIV-1 Patients with Primary InfectionScience, 1993
- Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous seraAIDS, 1990
- Animal models of human immunodeficiency virus infectionAntiviral Research, 1989